pharmaceuticals

Johnson & Johnson Logo

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson (NYSE: JNJ) reported first-quarter results before markets opened Tuesday. The health care giant reported quarterly adjusted diluted earnings per share (EPS) of $1.54 on revenue of $18.1 ...
Read Full Story »
buy sell

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences Inc. (NASDAQ: GILD) may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs, but an excessive multiyear performance above and ...
Read Full Story »
biotech

Why Questcor Buyout Will Not Deter Short Sellers

The $5.6 billion acquisition of Questcor Pharmaceuticals Inc. (NASDAQ: QCOR) by specialty drugmaker Mallinckrodt PLC (NYSE: MNK) started the week off with a big bang. Shares of Questcor originally leaped ...
Read Full Story »
Food and Drug Administration logo

FDA Keeps Driving Up Future Cost of Inhalable Insulin

MannKind Corp. (NASDAQ: MNKD) is suffering another setback from the U.S. Food & Drug Administration. While the FDA has been far from a friend to MannKind over the past few ...
Read Full Story »
research

Credit Suisse Says Grit Your Teeth and Buy Biotech

For the second time since late February, a huge run on the momentum, and specifically biotech, names hit the market last week. Again, the biotech benchmark took a huge 4% ...
Read Full Story »
DNA

Pancreatic Cancer Trial Enrollment Halt Damages Halozyme

Halozyme Therapeutics Inc. (NASDAQ: HALO) will need some therapeutics of its own, as are its shareholders. Its shares got pounded Friday morning on news of a temporary halt of its ...
Read Full Story »
biotech

Amgen Faces Cool Reception Over GSK Pact Termination

Amgen Inc. (NASDAQ: AMGN) submitted an SEC Filing showing that, as of April 1, its Amgen Manufacturing Ltd. subsidiary and GlaxoSmithKline PLC (NYSE: GSK), via Glaxo Group Ltd., have terminated ...
Read Full Story »
76764023

Can MannKind Shares Double Again on FDA Approval? (Final)

MannKind Corp. (NASDAQ: MNKD) has a serious victory within its grasp. The company has struggled to get its Afrezza inhalable insulin to market for years, and that dream now seems ...
Read Full Story »
153576724

Vindication for MannKind With FDA Panel Backing

MannKind Corp. (NASDAQ: MNKD)had been trading as though the stock was bracing for an U.S. Food and Drug Administration (FDA) panel decision recommending against the approval of its inhalable insulin ...
Read Full Story »
SupremeCourt

Teva’s Latest Victory in Effort to Protect Key Patents

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) shares reached a new multiyear high Monday after the U.S. Supreme Court agreed to hear its appeal to revive a patent that would protect ...
Read Full Story »
research

Biotech Firm Prana Misses Goal on Alzheimer Drug

Australia-based biotech firm Prana Biotechnology Ltd. (NASDAQ: PRAN) announced Monday morning that top-line results for a Phase II trial of its Alzheimer drug failed to meet its primary endpoint. Shares ...
Read Full Story »
Merger

Baxter Split-Up, a Page From Abbott’s Playbook

Baxter International Inc. (NYSE: BAX) is taking an activist investor role of its own. The health care company has announced that it is splitting itself into two separate companies, in ...
Read Full Story »
Pfizer logo

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

With the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to ...
Read Full Story »
biotech

Insmed Joins Biotech Trash Heap

When a drug trial goes bad, the hit to a drug maker's stock is instant and spectacular. Wednesday it will be Insmed Inc. (NASDAQ: INSM) in the spotlight. The company ...
Read Full Story »
Biotechnology word cloud

Short Sellers Find Renewed Interest in Biotech Stocks

24/7 Wall St. has tracked the short interest in leading biotech and emerging pharmaceutical stocks. After retreating from many of these stocks in the previous two periods, short sellers returned ...
Read Full Story »